Jonathan P. Foster - 20 Jun 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan P. Foster
Issuer symbol
MBRX
Transactions as of
20 Jun 2025
Transactions value $
$99,542
Form type
4
Filing time
23 Jun 2025, 16:35:31 UTC
Previous filing
18 Jun 2025
Next filing
21 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Foster Jonathan P. Chief Financial Officer C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON /s/ Jonathan P. Foster 23 Jun 2025 0001545414

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +2.71K +22.6% 14.7K 20 Jun 2025 Direct F1
transaction MBRX Common Stock Tax liability -$176 -661 -4.5% $0.27 14K 20 Jun 2025 Direct F2
transaction MBRX Common Stock Options Exercise +4.33K +30.82% 18.4K 22 Jun 2025 Direct F1
transaction MBRX Common Stock Tax liability -$281 -1.05K -5.74% $0.27 17.3K 22 Jun 2025 Direct F2
transaction MBRX Common Stock Purchase $100K +270K +1560.72% $0.37 288K 23 Jun 2025 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -2.71K -1.16% $0.00 232K 20 Jun 2025 Common Stock 2.71K Direct F1, F3
transaction MBRX Restricted Stock Units Options Exercise $0 -4.33K -1.87% $0.00 228K 22 Jun 2025 Common Stock 4.33K Direct F1, F4
transaction MBRX Series E Warrants Purchase -811K -43.85% 1.04M 23 Jun 2025 Common Stock 811K $0.37 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On June 20, 2022, the reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
F4 On June 22, 2023, the reporting person was granted 17,313 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
F5 On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.